LENVAKAST-10 Capsules LENVAKAST-10 contains Lenvatinib, a synthetic multiple receptor tyrosine kinase (RTK) inhibitor that targets vascular endothelial growth factor receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). It also inhibits other RTKs implicated in pathogenic angiogenesis, tumor growth, and cancer progression, including fibroblast growth factor receptors (FGFR1–4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET. By selectively inhibiting these receptor pathways, lenvatinib suppresses tumor vascularization, blocks downstream cell signaling, and impairs tumor cell proliferation. It is indicated for the treatment of locally recurrent or metastatic, progressive, radioiodine-refractory differentiated thyroid cancer (DTC), advanced renal cell carcinoma (RCC) in combination regimens, and unresectable hepatocellular carcinoma (HCC).